Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial


The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.

No comments:

Post a Comment